Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Cancer Discov. 2014 Jun 3;4(9):1046–1061. doi: 10.1158/2159-8290.CD-14-0337

Figure 5.

Figure 5

AZD9291 induces significant and sustained tumor regression in transgenic models of EGFR-TKI sensitising (C/L858R) and T790M resistant (C/L+T) lung cancer. A, Percent change in radiographic tumor volume from baseline by treatment for individual lung tumor-bearing C/L858R (top) and C/L+T (middle, bottom) animals with vehicle, afatinib (7.5 mg/kg/day), or AZD9291 (5 mg/kg/day). B and C, Representative MRI images and H&E staining (original magnification, ×40) of lungs from tumor-bearing animals (B, C/L858R and C, C/L+T) pre and post treatment with vehicle, afatinib, or AZD9291 for 1 week. H – heart; L – liver; arrow denotes tumor.